Skip to main content

Table 2 Changes in Medication Costs for Subgroupsa

From: Medication costs during an 18 month clinical trial of obesity treatment among patients encountered in primary care

 

Month 0

Month 6

Month 18

Change: Month 0 to Month 6; p value

Change: Month 6 to Month 18; p value

Change: Month 0 to Month 18; p value

Diabetes (DM)

281.56

298.01

250.66

16.45

−47.36

−30.9

or Hypertension

(59.89)

(66.34)

(56.42)

(95.95);

(97.21);

(91.27);

(HTN) (n = 59)

   

0.57

0.31

0.37

10 % weight

232.78

215.38

213.48

−17.4

−1.9

−19.3

lossa, b

(102.17)

(92.43)

(94.8)

(150.74);

(148.22);

(160.1);

(n = 21)

   

0.45

0.49

0.45

DM or HTN and

256.05

235.86

233.43

−20.2

−2.43

−22.63

10 % weight

(102.85)

(93.18)

(96.77)

(151.39);

(152.07);

(161.71);

lossa, b (n = 19)

   

0.45

0.49

0.44

  1. a Data are presented as mean (se) in 2013 U.S. dollar amounts
  2. a, b Participants who lost at least 10 % of starting weight from month 0 to month 6